B+
Bull case
30%
Probability
Target price
$880.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
REGN
RegeneronCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The near-term bull case is that the Q1 print still showed strong underlying earnings power: revenue grew 19%, Dupixent profit share accelerated, Libtayo remained strong, and EYLEA HD demand grew despite inventory and pricing friction. The packet's trusted-news set framed the quarter as an earnings beat, but detailed T+1 analyst estimate and target revisions were not available, so this is supportive rather than decisive evidence.
Posture
Mixed
Lead driver
Sentiment
What changed
7 setup hits (3d) with net bullish as of 2026-09-09.
What can break
EYLEA franchise erosion remains the main risk, with management warning that additional U.S. biosimilar competition is expected in the second half of 2026. [#10-Q-2026-04-29]
Momentum
70
Value
64
Sentiment
59
Setup hits (3d)
7 · Net Bullish
AI TargetsBase $780.00 · Bull $880.00 · Bear $620.00Analysis 2026-04-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $855.72
Why
Momentum70 · Δ7d -20.0
Value64 · Δ7d -0.0
Sentiment59 · Δ7d +8.5
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 7 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +8.5.
Contradictions & invalidation
- • EYLEA franchise erosion remains the main risk, with management warning that additional U.S. biosimilar competition is expected in the second half of 2026. [#10-Q-2026-04-29]
- • GAAP gross-margin guidance was reduced after a temporary manufacturing interruption in Limerick, Ireland; management expects ongoing impact until production returns to normal by the end of Q2 2026. [#8-K-2026-04-29]
- • The bear case is that the stock reaction focused on the quality of growth rather than the headline beat: total U.S.
Catalyst clock
2026-04-29
Q1 beat offset by EYLEA mix pressure and lower gross-margin outlook
Lead driver: Sentiment · See AI snapshot
Momentum
70
9% active weight
Current posture
7d trendSoftening
Δ7d
-20.0
Δ21d
-21.9
Value
64
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
0.0
Sentiment
59
62% active weight
Current posture
7d trendImproving
Δ7d
+8.5
Δ21d
+4.2
Why this grade
Composite grade C. Momentum 69.8 / Value 64.1 / Sentiment 58.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-29. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$780.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$620.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$82.97B
Beta
0.40
Shares Out
102.96M
P/E (TTM)
18.1
P/S (TTM)
5.63
P/FCF (TTM)
22.26
Rev YoY
+16.7%
EPS YoY
-4.5%
Gross Margin
+81.5%
Op Margin
+26.9%
Net Debt
-$5.64B
Current Ratio
3.34
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data